-Reuters
Related Posts
Wells Fargo Initiates Coverage On Halozyme Therapeutics with Overweight Rating, Announces Price Target of $65
Wells Fargo analyst Mohit Bansal initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Overweight rating and announces Price Target of $65.
Morgan Stanley Maintains Overweight on CarMax, Lowers Price Target to $140
Morgan Stanley maintains CarMax (NYSE:KMX) with a Overweight and lowers the price target from $165 to $140.
CF Acquisition Names Jane Novak As Interim CFO
Effective July 8, 2021, the board of directors (the “Board”) of CF Acquisition Corp. V (the “Company”) appointed Jane Novak as interim Chief Financial Officer of the Company. Additionally, the